Drug Profile


Alternative Names: Human recombinant TGF beta 3; Juvista; RN 1001

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Renovo
  • Developer Renovo; Shire
  • Class Recombinant proteins; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Scars; Vascular restenosis

Most Recent Events

  • 03 Mar 2011 Shire terminates its licence for avotermin in USA, Canada and Mexico
  • 03 Mar 2011 Discontinued - Phase-III for Scars in Denmark (Intradermal)
  • 03 Mar 2011 Discontinued - Phase-III for Scars in France (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top